Xeljanz (tofacitinib)
- Region
- 🇪🇺 EU
- Active substance
- tofacitinib
- Company
- Pfizer Limited
- Status
- Refused
- Therapeutic area
- Arthritis, Rheumatoid
- CHMP opinion
- Thu 25 Apr 2013
- Application
- EMEA/H/C/002542
- Official record
- www.ema.europa.eu
Indication
Treatment of rheumatoid arthritis.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Inijaq Opinion · Gedeon Richter Plc.
- 🇪🇺 Xeljanz Authorised · Pfizer Europe MA EEIG
Follow Xeljanz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.